DOCSLIB.ORG

Ep 2421508 B1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 2421508 B1 (19) TZZ _Z_T (11) EP 2 421 508 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/14 (2006.01) 14.12.2016 Bulletin 2016/50 (86) International application number: (21) Application number: 10716464.2 PCT/DK2010/000056 (22) Date of filing: 26.04.2010 (87) International publication number: WO 2010/121620 (28.10.2010 Gazette 2010/43) (54) PARTICULATE MATERIAL FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS PARTIKELFÖRMIGES MATERIAL ZUR VERZÖGERTEN WIRKSTOFFFREISETZUNG MATIÈRE PARTICULAIRE POUR LA LIBÉRATION CONTRÔLÉE DE PRINCIPES ACTIFS (84) Designated Contracting States: • ANDERSEN, Jette, Bæk AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-7100 Vejle (DK) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (74) Representative: Plougmann Vingtoft a/s Rued Langgaards Vej 8 (30) Priority: 24.04.2009 US 172474 P 2300 Copenhagen S (DK) (43) Date of publication of application: (56) References cited: 29.02.2012 Bulletin 2012/09 EP-A1- 1 974 807 EP-A1- 2 168 572 WO-A1-2008/055006 WO-A2-2005/072125 (73) Proprietor: Omya International AG GB-A- 1 572 718 US-A- 1 171 392 4665 Oftringen (CH) US-A- 5 633 027 (72) Inventors: Remarks: • PEDERSEN, Kurt, Møller Thefile contains technical information submitted after DK-7323 Give (DK) the application was filed and not included in this specification Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 421 508 B1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 421 508 B1 2 Description of the chewing gum, the particulate material comprising a combination of one or more active ingredients, exclud- FIELD OF THE INVENTION ing nicotine, and an inorganic mineral filler comprising natural calcium carbonate and/or precipitated calcium [0001] The present invention relates to the field of5 carbonate, where the inorganic mineral filler is obtainable chewing gum for controlled release of active ingredients, by pre-treatment with one or more medium-strong to + such as a flavoring agent. In particular, the present in- strong sources of H3O ions and/or pre-treatment with vention relates to a chewing gum comprising a chewing an inorganic salt, and pre-treatment with gaseous CO2, gum core with at least one sub-layer, wherein a particu- wherein the active ingredient is reversibly absorbed into late material for controlled release of active ingredients 10 and/or adsorbed onto the inorganic mineral filler, wherein is added to said at least one sub-layer or both the sub- the BET specific surface area of the inorganic mineral layer and the core of the chewing gum, the particulate filler is above 15 m2/g, the BET specific surface area material comprising a combination of one or more active measured in accordance with ISO 9277 and wherein the ingredients, excluding nicotine, and an inorganic mineral at least one sub-layer is between the chewing gum core filler comprising natural calcium carbonate and/or pre- 15 and an outer coating cipitated calcium carbonate, where the inorganic mineral [0006] WO2008/055006 discloses a long flavor dura- filler is obtainable by pre-treatment with one or more me- tion releasing structure comprising: i) a thermoplastic cel- + dium-strong to strong sources of H3O ions and/or pre- lulose material, a non-cellulosic thermoplastic polymer, treatment with an inorganic salt, and pre-treatment with and a porous flavor reservoir material; and ii) a flavoring 20 gaseous CO2, wherein the active ingredient is reversibly agent incorporated into the structure. The porous flavor absorbedinto and/or adsorbedonto the inorganic mineral reservoir material is selected from silica, talc, titanium filler, wherein the BET specific surface area of the inor- dioxide, calcium carbonate, mannitol, maltodextrin and ganic mineral filler is above 15 m2/g, the BET specific mixtures thereof. D4 further relates to a chewing gum surface area measured in accordance with ISO 9277 and composition with a long flavor duration releasing struc- whereinthe atleast onesub-layer isbetween thechewing 25 ture. gum core and an outer coating. [0007] The inorganic mineral filler of the present inven- tion provides a surprisingly high loading capacity of active BACKGROUND OF THE INVENTION ingredients, such as flavoring agents. The high loading capacity may be a benefit in a number of applications. [0002] It is a general understanding that controlled re- 30 One advantage is that a higher content of active ingre- lease of active ingredients may be a critical parameter in dients may be applied. Another advantage is that active terms of the ability to deliver an active ingredient in the ingredients may be effectively separated from other in- mostsuitable manner. This appliesto confectionery prod- gredients in the formulation, whereby unfavorably inter- ucts where a controlled release of active ingredients, action between the ingredients may be avoided. Yet an- such as nutraceuticals or oral care agents, is critical to 35 other advantage is that a high loading capacity implies a give the desired effect. This applies also to pharmaceu- better stability of active ingredient. tical products where active pharmaceutical ingredients [0008] In addition, the active ingredient is reversibly may be harmfull or even lethal in a high dose. In addition absorbedinto and/oradsorbed onto theinorganic mineral it may be beneficial that the release of active ingredients filler, which is highly advantageous in order for a control- is controlled in order to achieve an improved experience 40 led release of active ingredients. of the product, such as a better taste of the product or a [0009] The particulate material of the present invention masking effect. may give an immediate release of active ingredients or [0003] Although various solutions have been provided may be designed to sustain the release for longer peri- in the past, the solutions imply several drawbacks, which ods. In particular the present invention may provide sus- have been difficult or sometimes impossible to solve. 45 tained release of active ingredients in a much better way compared to the prior art. The porous nature of inorganic SUMMARY OF THE INVENTION mineral filler, such as natural calcium carbonate, offers a much better stability of the active ingredients, and is [0004] The present inventors have surprisingly found tasteless, stabile and biocompatible. It exhibits good that inorganic mineral filler, such as natural calcium car- 50 compactability in drug mixtures. bonate, is a highly suitable carrier of active ingredients, [0010] Compared to other carrier materials, natural such as a flavoring agent, without the drawbacks of the calcium carbonate may in particular be useful. The prior art. present invention is particularly suitable for delivery of a [0005] In one aspect the present invention pertains to flavoring agent. The present invention is suitable for con- a chewing gum comprising a chewing gum core with at 55 trolled release in chewing gum. least one sub-layer, wherein a particulate material for [0011] As disclosed herein chewing gum is used as controlled release of active ingredients is added to said the delievery dehicle. at least one sub-layer or both the sub-layer and the core [0012] Accordingly, there is provided a particulate ma- 2 3 EP 2 421 508 B1 4 terial for controlled release of active ingredients, the par- [0020] The present invention concerns a particulate ticulate material comprising a combination of one or more material for controlled release of active ingredients, the active ingredients, excluding nicotine, and an inorganic particulate material comprising a combination of one or mineral filler, wherein the active ingredient is reversibly more active ingredients, excluding nicotine, and an inor- absorbedinto and/or adsorbedonto the inorganic mineral 5 ganic mineral filler, wherein the active ingredient is re- filler, and wherein the BET specific surface area of the versibly absorbed into and/or adsorbed onto the inorgan- inorganic mineral filler is above 15 m 2/g, the BET specific ic mineral filler, and wherein the BET specific surface surface area measured in accordance with ISO 9277. area of the inorganic mineral filler is above 15 m 2/g, the BET specific surface area measured in accordance with DETAILED DESCRIPTION 10 ISO 9277. [0021] The active ingredient according to the present [0013] The present invention provides for a particulate invention may be any active ingredient which is absorbed material, where an active ingredient is absorbed into into or adsorbed onto the particulate material, excluding and/or adsorped onto an inorganic mineral filler, such as nicotine. Suitable APIs are preferably selected among natural calcium carbonate. Thereby the active ingredient, 15 the below listed compounds. such as a flavoring agent, is stabilised. The release of [0022] Teeth whitening actives may be included in the the active ingredient from the active ingredient-carbonate present invention. The actives suitable for whitening are mixture may be immediate or may be controlled so that selected from the group consisting of oxalates, perox- the active ingredient is delivered at a pre-determed time. ides, metal chlorites, perforates, percarbonates, peroxy- [0014] The term "compressed chewing gum" is used 20 acids, and mixtures thereof Suitable peroxide com- in thisdocument to indicatea chewing gum manufactured pounds include hydrogen peroxide, calcium peroxide, by compressing granules and optionally other ingredi- sodium peroxide, carbamide peroxide, urea peroxide, ents at a certain pressure to obtain a chewing gum. The sodium percarbonate and mixtures thereof.
Load more

Recommended publications
  • Par Drugs and Chemicals Limited
    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
    [Show full text]
  • United States Patent [19] [11] Patent Number: 4,704,278 Wu Et Al
    United States Patent [19] [11] Patent Number: 4,704,278 Wu et al. [45] Date of Patent: :1: Nov. 3, 1987 [54] FLUIDIZED MAGALDRATE SUSPENSION 4,117,116 9/1978 Buehler et a1. .................... .. 424/158 [75] Inventors: Chien-Chin Wu, Wilmington, Del.; OTHER PUBLICATIONS Gerald L‘ Renter’ Plattsburgh’ NY‘ Handbook on Nonprescription Drugs, Fifth Edition [73] Assignee: American Home Products Corp (Del), (1977), p. 16, American Pharmaceutical Assoc, Wash. New York, N.Y. D.C. [ * 1 Notice The portion of the term of this patent Primary Examiner-Frederick E. Waddell subsequent to Jun. 30, 2004 has been disclaimed. [57] ABSTRACT , [211 App], N03 395,012 An aqueous antacid composition of magaldrate gel and _ . a process for preparing same are described by the inven [22] F11e d'' A ug' 8 ’ 1986 t1on.- The composltlon- - is prepared from and contains _ . precipitated and undried magaldrate gel and a ?uidizing Related U‘S' Apphcatlon Data of a ?rst and second ?uidizer. On fluidizer is provided [63] Continuation of Ser. No. 661,648, Oct. 17, 1984, aban~ by an aluminum hydroxide gel having colloidal proper doned’ ties and the second by a pharmaceutically acceptable [51] Int. (:1.4 ............................................ .. A61K 33/08 citrate ion source including citric acid- The Process and [52] US. Cl. .............. .. 424/157; 424/158 compositiw are characterized in Providing a ?uid, [5 8] Field of Search .............................. .. 424/157, 158 resuspendlble, pharmaceutically elegant suspension POS _ ' sessing high antacid capacity and stability at even ele [56] References cued vated magaldrate concentrations in addition to the abil U.S. PATENT DOCUMENTS ity to ?uidize stiff, paste-like magaldrate gel cakes.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct
    USOO525371 1A United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct. 19, 1993 54) PROCESS FOR DECOMPOSING 2,268,215 12/1941 Kerr ...................................... 127/33 POLYSACCHARDES IN ALKALINE 3,167,510 /1965 Alter ..... sa as A8 a X8 a P. 252/8.551 3,655,644 4/1972 Durand ........................... 106/21 X AQUEOUS SYSTEMS 3,935,187 1/1976 Speakman ........................... 536/102 75 Inventor: Thomas C. Mondshine, Houston, 4,202,795 5/1980 Burnham et al. ............... 166/308 X Tex. 4,552,668 11/1985 Brown et al. ................... 166/300X Lachenal et al. ..................... 162/25 Assignee: Texas United Chemical Corp., 4,787,959 11/1988 (73) Primary Examiner-George A. Suchfield Houston, Tex. Attorney, Agent, or Firm-Roy F. House 21 Appl. No.: 844,167 57 ABSTRACT 22 Filed: Mar. 2, 1992 Alkaline earth metal or transition metal peroxides are (51) int. Cli.............................................. E21B 43/26 used as a delayed breaker in alkaline aqueous fluids 52) U.S. C. .................................... 166/300; 166/308; containing a water soluble hydrophilic polysaccharide 252/8.551; 252/326 polymer hydrated therein. The peroxide is activated by (58) Field of Search ............................... 166/300, 308; increasing the temperature of the fluid. The invention is 252/8.551, 326,358; 536/41, 80, 88 particularly useful for the delayed break of hydraulic 56) References Cited fracturing fluids containing hydroxypropyl guar poly c. U.S. PATENT DOCUMENTS i,953,398 4/1934 Eskew ................................... 536/41 10 Claims, No Drawings 5,253,711 1. 2 G. W. Hawkins, and H. D. Brannon, Feb.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Name Acicone-S Magaldrate Simethicone Antacid, Antiflatulent / Fast, Sustained Relief Suspension - Chewable Tablet Composition Sodium-Free / Sugar-Free
    Name Acicone-S Magaldrate Simethicone Antacid, Antiflatulent / Fast, Sustained Relief Suspension - Chewable Tablet Composition Sodium-Free / Sugar-Free Active: Each 5 ml suspension contains: Magaldrate 540 mg, Simethicone 40 mg Each tablet contains: Magaldrate 720 mg, Simethicone 25 mg Inactives: - Suspension: Propyl paraben, Methyl paraben, Saccharine, Polysorbate 80, Spearmint natural flavour, Sorbitol 70% solution, Propylene glycol, Xanthan gum, Methyl cellulose, Glycerin and Purified water. - Tablet: Sorbitol powder, Gelatin powder, Peppermint dry flavour, Colloidal silicon dioxide, Aspartam fine powder, Polysorbate 80, Magnesium stearate and Mannitol powder. Pharmacological Action Antacid &Anti-flatulent. Acicone-S is an antacid containing a combination of magaldrate and simethicone as active ingredients. Magaldrate (aluminium magnesium hydroxide sulfate) is a chemical entity of aluminium and magnesium hydroxides (not a physical mixture), while simethicone (activated dimethicone) is an anti flatulent. Acicone-S provides a true buffering action with high acid consuming properties allowing an immediate and sustained relief of symptoms associated with oesophageal and gastric hyperacidity with no alkalinization or acid rebound effect. Acicone-S is distinguished by a strong acid insulating power forming a thin film covering the gastric mucous membranes to resist the transfer of hydrogen ions across the film, allowing more protection to the wall of the stomach. Acicone-S effectively adsorbs and binds a considerable amount of substances contained in the duodeno-gastric reflux, such as pepsin, bile acids and lysolecithin; all these substances are aggressor factors in the case of gastritis, peptic ulcer and oesophagitis. Acicone-S thus offers a better protection to the walls of the upper gastro-intestinal tract. Acicone-S assures a higher safety margin especially for both hypertensive and diabetic patients as being sodium-free and sugar-free, respectively.
    [Show full text]
  • Photometric Method for Estimation of Magaldrate
    The Pharma Innovation Journal 2015; 4(6): 60-63 ISSN: 2277- 7695 TPI 2015; 4(6): 60-63 Photometric method for estimation of Magaldrate © 2015 TPI www.thepharmajournal.com Received: 18-06-2015 Krishnasis Chakraborty, Mubeen G, Ritu Kimbahune, Lalitha N, Yajnesh Pai Accepted: 19-07-2015 Abstract Krishnasis Chakraborty The complex formation between Magaldrate, Magnesium and Aluminium hydroxide salt, and Department of Quality Eriochrome Black T at pH10 has been proposed for photometric estimation of Magaldrate. The Assurance, Al-Ameen College of absorbance of stable violet colored complex of Eriochrome Black T and Magnesium and Aluminium ions Pharmacy, Opposite to Lalbagh of Magaldrate was measured at 527 nm and used for quantitation by single point method. The method has Main Gate, Hosur road, been successfully employed for Magaldrate tablets and the obtained results were found complying with Bangalore-27, India. official specification. The method has been validated as per ICH guidelines and the results for all the Mubeen G parameters were found in the recommended limits. Department of Quality Assurance, Al-Ameen College of Keywords: Magaldrate, Eriochrome Balck T, Chemical derivatization. Pharmacy, Opposite to Lalbagh Main Gate, Hosur road, Introduction Bangalore-27, India. Current life style and diet regime have increased the use of Antacids which are available in different dosage forms. Magaldrate is one of the commonly prescribed antacid which provides Ritu Kimbahune fast and long lasting acid neutralization, long term stability and distinct adsorption capability Department of Quality [1, 2] Assurance, Al-Ameen College of with respect to pepsin, bile acid and lysolecithin . 3 Pharmacy, Opposite to Lalbagh Magaldrate (MG), Al5Mg10(OH)31(SO4)2.X H2O, a Magnesium and Aluminium hydroxide salt Main Gate, Hosur road, is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and Bangalore-27, India.
    [Show full text]
  • Chemical List
    1 EXHIBIT 1 2 CHEMICAL CLASSIFICATION LIST 3 4 1. Pyrophoric Chemicals 5 1.1. Aluminum alkyls: R3Al, R2AlCl, RAlCl2 6 Examples: Et3Al, Et2AlCl, EtAlCl2, Me3Al, Diethylethoxyaluminium 7 1.2. Grignard Reagents: RMgX (R=alkyl, aryl, vinyl X=halogen) 8 1.3. Lithium Reagents: RLi (R = alkyls, aryls, vinyls) 9 Examples: Butyllithium, Isobutyllithium, sec-Butyllithium, tert-Butyllithium, 10 Ethyllithium, Isopropyllithium, Methyllithium, (Trimethylsilyl)methyllithium, 11 Phenyllithium, 2-Thienyllithium, Vinyllithium, Lithium acetylide ethylenediamine 12 complex, Lithium (trimethylsilyl)acetylide, Lithium phenylacetylide 13 1.4. Zinc Alkyl Reagents: RZnX, R2Zn 14 Examples: Et2Zn 15 1.5. Metal carbonyls: Lithium carbonyl, Nickel tetracarbonyl, Dicobalt octacarbonyl 16 1.6. Metal powders (finely divided): Bismuth, Calcium, Cobalt, Hafnium, Iron, 17 Magnesium, Titanium, Uranium, Zinc, Zirconium 18 1.7. Low Valent Metals: Titanium dichloride 19 1.8. Metal hydrides: Potassium Hydride, Sodium hydride, Lithium Aluminum Hydride, 20 Diethylaluminium hydride, Diisobutylaluminum hydride 21 1.9. Nonmetal hydrides: Arsine, Boranes, Diethylarsine, diethylphosphine, Germane, 22 Phosphine, phenylphosphine, Silane, Methanetellurol (CH3TeH) 23 1.10. Non-metal alkyls: R3B, R3P, R3As; Tributylphosphine, Dichloro(methyl)silane 24 1.11. Used hydrogenation catalysts: Raney nickel, Palladium, Platinum 25 1.12. Activated Copper fuel cell catalysts, e.g. Cu/ZnO/Al2O3 26 1.13. Finely Divided Sulfides: Iron Sulfides (FeS, FeS2, Fe3S4), and Potassium Sulfide 27 (K2S) 28 REFERRAL
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,645,535 B2 Zyck Et Al
    USOO6645535B2 (12) United States Patent (10) Patent No.: US 6,645,535 B2 Zyck et al. (45) Date of Patent: *Nov. 11, 2003 (54) METHOD OF MAKING COATED CHEWING FR 2 635 441 2/1990 GUMPRODUCTS CONTAINING WARIOUS FR 2 706 771 6/1993 ANTACIDS GB O 934,596 8/1963 GB O 963 518 7/1964 GB 1489,832 10/1977 (75) Inventors: Daniel J. Zyck, North Riverside, IL GB 2181646 A 4/1987 (US); Michael J. Greenberg, IT O2173487 7/1997 Northbrook, IL (US); David G. IT O1293655 3/1999 Barkalow, Deerfield, IL (US); Scott W. JP 1991-112450 5/1991 Marske, LaGrange, IL (US); Philip G. JP 1991-251533 11/1991 Schnell, Downers Grove, IL (US); JP 1994-303911 11/1994 Philip Mazzone, Griffith, IN (US) JP 1996-19370 1/1996 JP 86/242561 10/1996 (73) Assignee: WM. Wrigley Jr. Company, Chicago, KR 94-2868 4/1994 WO WO 84/02271 6/1984 IL (US) WO WO 90/12511 11/1990 WO WO 90/12583 11/1990 (*) Notice: Subject to any disclaimer, the term of this WO WO 92/06680 4/1992 patent is extended or adjusted under 35 WO WO95/OOO38 1/1995 U.S.C. 154(b) by 53 days. WO WO95/OOO39 1/1995 WO WO95/10290 4/1995 This patent is Subject to a terminal dis WO WO 96/OOO70 1/1996 claimer. WO WO 96/03975 2/1996 WO WO 97/21424 6/1997 WO WO 97/24036 6/1997 (21) Appl. No.: 09/747,323 WO WO 98/231.65 6/1998 (22) Filed: Dec.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • A Review on Pharmacology and Therapeutic Uses of Antacids
    International Journal for Environmental Rehabilitation and Conservation ISSN: 0975 — 6272 XI (SP2): 114 — 119 www.essence-journal.com Review Article A review on pharmacology and therapeutic uses of Antacids Saraswat Renu1, Chatterji Nupur1 and Saraswat Devesh2 1Department of Chemistry, Meerut college, Meerut, India 2Department of chemistry, Eicher School, Faridabad, India Corresponding Author: [email protected]; [email protected] A R T I C L E I N F O Received: 20 July 2020 | Accepted: 15 August 2020 | Published Online: 30 September 2020 EOI: 10.11208/essence.20.11.SP2.136 Article is an Open Access Publication. This work is licensed under Attribution-Non Commercial 4.0 International (https://creativecommons.org/licenses/by/4.0/) ©The Authors (2020). Publishing Rights @ MANU—ICMANU and ESSENCE—IJERC. A B S T R A C T Antacids have been used since the last more than hundred years for the symptomatic relief by raising the pH of the stomach and without hampering the gastric condition of the body namely killing of bacteria. Sodium bicarbonate, aluminium hydroxide, magnesium hydroxide besides ranitidine and the prazoles react with the HCL present in the stomach and have become the ready choice of physicians to treat all kinds of gastric disorders. This study sheds a light on the pharmacokinetics of various antacids, their advantages, disadvantages and the chemical conditions which they help to subside. Present paper specifically focuses on the study of clinical uses and side effects of long run use of antacids K E Y W O R D S Antacids | Gastric pH | GERD | Ulcer C I T A T I O N Saraswat, Renu; Chatterji, Nupur and Saraswat, Devesh (2020): A review on pharmacology and therapeutic uses of Antacids.
    [Show full text]